Nov 09, 2022
Immutep Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC at SITC 2022 Annual Meeting
Immutep Announces Promising Initial Clinical Data from INSIGHT-003 at SITC 2022
Immutep Granted New Patents in Japan and South Korea for First-in-Class LAG-3 Candidate, Eftilagimod Alpha in Chemo-Immunotherapy Combination
Nov 03, 2022
Immutep Announces Abstract Highlighting Eftilagimod Alpha Selected for SITC 2022 Annual Meeting Press Conference
Nov 02, 2022
Immutep to Participate in Two Upcoming Investor Conferences
